HEAD & NECK

1.	Hamartome im Kopf-Hals-Bereich
	Dr. med. Knopke, S. 2015-01-01
	TIBGERLIB-DE
2.	Systematic Review of Tobacco Use After Lung or Head/Neck Cancer Diagnosis: Results and Recommendations for Future Research.
	Burris, Jessica L 2015-08-17
	PMID:26282629
	SCIGOV-EN
3.	Palliative head and neck radiotherapy with the RTOG 8502 regimen for incurable primary or metastatic cancers.
	Lok, Benjamin H 2015-08-14
	PMID:26282714
	SCIGOV-EN
4.	Book Review: A Century of Progress in Head & Neck Cancer.
	Palma, Gina L 2015-08-17
	PMID:26282587
	SCIGOV-EN
5.	Prognostic value of S100/CD31 and S100/podoplanin double immunostaining in mucosal malignant melanoma of thehead and neck.
	Wermker K 2015-09-01
	BACKGROUND: In uncommon mucosal melanomas of the head and neck established prognostic factors are rare and controversially discussed. The purpose of this study was to evaluate outcome and value of S100/podoplanin and S100/CD31 double immunostaining in head and neck mucosal melanomas. METHODS: Retrospectively, patients withhead and neck mucosal melanomas treated between 1973 and 2008 were analyzed. S100/podoplanin and S100/CD31 immunostaining were performed to detect lymph vessel invasion (LVI) and blood vessel invasion (BVI). Predictive parameters for disease-specific survival (DSS) were identified using univariate and multivariate statistics. RESULTS: Forty-two patients with head and neck mucosal melanoma were included. Three-year, 5-year, and 10-year DSS rates were 59%, 44%, and 20%, respectively. Age above 70 years, occurrence of distant metastasis, LVI, and BVI were significantly associated with shorter DSS time (p < .05), whereas localization at the conjunctiva showed better outcome. CONCLUSION: S100/podoplanin and S100/CD31 double immunostaining detect reliable LVI and BVI in headand neck mucosal melanoma and both are associated significantly with worse prognosis. © 2014 Wiley Periodicals, Inc. Head Neck 37: 1368-1374, 2015.
	UKPMC-EN
6.	PET Imaging in Head and Neck Cancer Patients to Monitor Treatment Response: A Future Role for EGFR-Targeted Imaging.
	van Dijk, Laura K 2015-08-15
	Approximately 50,000 new cases of head and neck squamous cell carcinoma (HNSCC) are diagnosed worldwide each year and subsequently treated with surgery, chemotherapy, radiotherapy, and/or targeted therapy. The heterogeneity of the patient population in terms of treatment response drives the search for tumor-specific biomarkers. Imaging of biomarkers can reveal patient-specific responses to therapies and, if assessed early after the start of treatment, may allow adaptation of treatment regimens. In this review, tracers that have been tested to monitor treatment efficacy in HNSCC by PET scanning prior to and early after the onset of treatment are discussed. An important imaging target for this application in HNSCC patients is the EGFR. It steers the pathways related to proliferation, hypoxia, DNA damage repair, and apoptosis, all treatment-resistance mechanisms. The anti-EGFR antibody cetuximab has been labeled with various radionuclides and has been tested as an imaging biomarker in several HNSCC models. These studies suggest that EGFR-targeting tracers can be used to monitor EGFR receptor expression in HNSCC and have the potential to noninvasively monitor cetuximab treatment and steer individualized treatment regimens. Multiple factors can influence the uptake of EGFR-targeting tracers. Here, we discuss the relevance of gene and protein overexpression, mutations, and amplifications related to EGFR signaling. In addition, monoclonal antibody properties and the effect on the host immune system are reviewed in light of the future role of EGFR-targeted imaging in HNSCC. Clin Cancer Res; 21(16); 3602-9. ©2015 AACR. PMID:25931452
	SCIGOV-EN
7.	The efficacy of superselective intra-arterial infusion with concomitant radiotherapy for adenoid cystic carcinoma of thehead and neck.
	Homma A 2015-09-01
	SCIGOV-EN
8.	HPV and EBV Infections in Neck Metastases from Occult Primary Squamous Cell Carcinoma: Another Virus-Related Neoplastic Disease in the Head and Neck Region.
	Bussu, Francesco 2015-08-19
	PMID:26286196
	SCIGOV-EN
9.	Spiral CT of the neck and nodal staging in head and neck malignomas
	2015-08-21 02:22:55.0
	Spiral computed tomography (CT) of the neck after bolus injection of a contrast medium was performed in a group of 30 patients. Details of the examination and its results are given. It is concluded that the sensitivity and specificity of spiral CT in the assessment of nodal involvement of cervical lymph nodes in head and neck tumors approach closely those of the conventional axial CT. The assets of the former technique include the possibility of reducing appreciably the total volume of the contrast medium and the feasibility of processing the data by Maximum Intensity Projection or Surface Shaded Display algorithms. 1 tab., 7 figs., 10 refs
	IAEA-INISDB-EN
10.	Improving guideline sensitivity and specificity for the identification of proactive gastrostomy placement in patients withhead and neck cancer.
	Brown, Teresa E 2015-08-13
	PMID:26268152
	SCIGOV-EN
11.	Analysis of Dysphagia Patterns Using a Modified Barium Swallowing Test Following Treatment of Head and NeckCancer.
	Lee SY 2015-09-01
	Full Text Available
	WWS-KOMED-EN
12.	Self-reported Tobacco use does not correlate with carcinogen exposure in smokers with head and neck cancer.
	Khariwala SS 2015-08-01
	SCIGOV-EN
13.	A Lethal Sequelae of Spinal Infection Complicating Surgery and Radiotherapy for Head and Neck Cancer.
	Cheung JP 2015-08-01
	Full Text Available
	WWS-KOMED-EN
14.	JP 2005245362-A/9: Method for prediction of a risk of lung cancer and head-and-neck cancer.
	2015-08-21 02:22:49.0
	Accession Number: DD223788 Sequence Length:2629 Molecular Type:DNA Organism:Homo sapiens
	WWS-DNADATA
15.	Safety and Tumor Specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer.
	Rosenthal, Eben L 2015-08-15
	PMID:25904751
	SCIGOV-EN
16.	Identification of human papillomavirus status specific biomarker in head and neck cancer.
	Kim KY 2015-09-01
	BACKGROUND: In an attempt to improve the prognosis of patients with head and neck cancer, it could be necessary to identify biomarkers in homogeneous subgroups of patients with head and neck cancer. METHODS: We explored the necessity of human papillomavirus (HPV) status-specific biomarkers in patients with head and neck cancer and identified an HPV status-specific gene set. The identified gene set was validated with the external microarray datasets. For this purpose, we used 4 microarray datasets obtained from a public database. One dataset was used for identifying the HPV status specific gene set, and the other datasets were used for validation. RESULTS: The identified gene set for distinguishing head and neck cancer from head and neck normal, did not accurately discriminate the HPV specific patients with head and neck cancer from the head and neck normal group. Also, it was demonstrated that some HPV-positive (HPV+) head and neck cancer-specific genes may not be significant in HPV-negative (HPV-) headand neck cancer patients. The identified HPV specific gene sets showed good performance in validation datasets. The HPV+ head and neck cancer-specific gene set included various metabolism-related pathways, and the HPV- head andneck cancer-specific gene set included several pathways; fibroblast, collagen degradation, actin-binding, and actin cytoskeleton. CONCLUSION: The identification of HPV status-specific significant gene set was necessary. It is expected that HPV status-specific biomarkers can be helpful in deciding therapeutic methods for patients with headand neck cancer, after biological validation and large prospective trials. © 2014 Wiley Periodicals, Inc. Head Neck 37: 1310-1318, 2015.
	UKPMC-EN
17.	Mouthwash use and cancer of the head and neck: a pooled analysis from the International Head and Neck Cancer Epidemiology Consortium.
	Boffetta, Paolo 2015-08-13
	PMID:26275006
	SCIGOV-EN
18.	[Clinical and paraclinical follow-up after radiotherapy for head and neck cancer].
	Clément-Colmou, K 2015-08-13
	PMID:26278985
	SCIGOV-EN
19.	JP 2007000052-A/13: Molecular Marker for Head and Neck Cancer.
	2015-08-21 02:22:49.0
	Accession Number: DD460060 Sequence Length:497 Molecular Type:DNA Organism:Homo sapiens
	WWS-DNADATA
20.	JP 2007000052-A/18: Molecular Marker for Head and Neck Cancer.
	2015-08-21 02:22:49.0
	Accession Number: DD460065 Sequence Length:439 Molecular Type:DNA Organism:Homo sapiens
	WWS-DNADATA